CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 84 enrolled
Drug / intervention
Fluoxetine +2 moredrug
Likely dose
Fluoxetine 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00834834
NCT00834834Phase 4Completed
CompareCT.gov

Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder: Predictors of Change

New York State Psychiatric Institute·interventional·Posted Feb 3, 2009·Updated Aug 18, 2017

In Brief

A Phase 4 clinical trial evaluating Fluoxetine, DBT, and 1 other intervention for Borderline Personality Disorder and Suicide. Completed, enrolled 84 participants across 1 site.

Detailed Summary

This study will compare the effectiveness of two treatments, dialectical behavior therapy versus fluoxetine with clinical management, for reducing the risk of self-injury and suicidal behavior in people with borderline personality disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBorderline Personality Disorder, Suicide
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 3, 2009
Enrollment StartMar 1, 2009
Primary CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 17.4 years ago

Interventions

Fluoxetinedrug

Starting dose of 20 mg daily will increase over 4 weeks, depending on tolerability, up to 40 mg daily. Treatment will last 6 months.

DBTbehavioral

One 60-minute individual therapy session and one 90-minute group therapy session every week. Treatment will last 6 months.

Citalopramdrug

Dose set by study psychiatrist, up to 60 mg daily. Treatment will last 6 months.